S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
S&P 500   4,305.20 (+0.19%)
DOW   34,152.01 (+0.71%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:CBAY

CymaBay Therapeutics - CBAY Stock Forecast, Price & News

$3.91
-0.14 (-3.46%)
(As of 08/16/2022 05:26 PM ET)
Add
Compare
Today's Range
$3.81
$4.05
50-Day Range
$1.91
$4.25
52-Week Range
$1.67
$4.74
Volume
449,811 shs
Average Volume
611,133 shs
Market Capitalization
$331.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.80

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.25 Rating Score
Upside/​Downside
181.3% Upside
$11.00 Price Target
Short Interest
Healthy
5.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.61mentions of CymaBay Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$100,037 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.23) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

134th out of 1,124 stocks

Pharmaceutical Preparations Industry

51st out of 555 stocks

CBAY stock logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CBAY shares. B. Riley decreased their price objective on CymaBay Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 18th. HC Wainwright cut their target price on CymaBay Therapeutics from $12.00 to $10.00 and set a "na" rating on the stock in a research note on Monday, May 16th. Oppenheimer cut their target price on CymaBay Therapeutics to $12.00 and set a "na" rating on the stock in a research note on Monday, May 16th. Finally, StockNews.com raised CymaBay Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday. One research analyst has rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, CymaBay Therapeutics currently has an average rating of "Buy" and a consensus target price of $11.00.

CymaBay Therapeutics Stock Performance

Shares of CBAY Stock traded down $0.14 during trading hours on Tuesday, hitting $3.91. 446,801 shares of the company's stock traded hands, compared to its average volume of 611,114. The stock's fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $2.87. CymaBay Therapeutics has a 12-month low of $1.67 and a 12-month high of $4.74. The company has a debt-to-equity ratio of 1.00, a current ratio of 13.27 and a quick ratio of 13.27.

CymaBay Therapeutics (NASDAQ:CBAY - Get Rating) last announced its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.01). During the same period in the prior year, the firm posted ($0.34) EPS. As a group, sell-side analysts predict that CymaBay Therapeutics will post -1.23 EPS for the current year.

Insider Buying and Selling

In related news, CEO Sujal Shah bought 51,301 shares of the firm's stock in a transaction on Monday, June 6th. The stock was acquired at an average cost of $1.95 per share, for a total transaction of $100,036.95. Following the purchase, the chief executive officer now owns 171,301 shares in the company, valued at $334,036.95. The acquisition was disclosed in a filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
CymaBay Therapeutics Misses Q2 EPS by 2c
Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
CymaBay Therapeutics: Q1 Earnings Insights
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Company Calendar

Last Earnings
8/11/2022
Today
8/16/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+176.2%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
3 Analysts

Profitability

Net Income
$-90,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.93 per share

Miscellaneous

Free Float
80,021,000
Market Cap
$331.09 million
Optionable
Optionable
Beta
0.68

Key Executives

  • Mr. Sujal A. Shah (Age 49)
    Pres, CEO & Director
    Comp: $873.87k
  • Dr. Dennis D. Kim M.B.A. (Age 52)
    M.D., MBA, Chief Medical Officer
    Comp: $406.11k
  • Mr. Lewis J. Stuart B.A. (Age 63)
    BA, M.B.A., MBA, Chief Commercial Officer
    Comp: $378.79k
  • Mr. Daniel Menold (Age 52)
    VP of Fin.
  • Dr. Charles A. McWherter Ph.D. (Age 67)
    Sr. VP & Chief Scientific Officer
  • Mr. Paul T. Quinlan (Age 59)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. Ken Boehm
    Sr. VP of HR
  • Mr. Patrick J. O'Mara (Age 61)
    Sr. VP of Bus. Devel.
  • Dr. Robert L. Martin (Age 60)
    Sr. VP of Manufacturing & Nonclinical Devel.
  • Ms. Klara A. Dickinson-Eason (Age 54)
    Chief Regulatory & Quality Assurance Officer













CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2022?

3 brokerages have issued 12 month price targets for CymaBay Therapeutics' stock. Their CBAY share price forecasts range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 171.6% from the stock's current price.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2022?

CymaBay Therapeutics' stock was trading at $3.38 at the beginning of 2022. Since then, CBAY stock has increased by 19.8% and is now trading at $4.05.
View the best growth stocks for 2022 here
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.01. During the same period last year, the business posted ($0.34) earnings per share.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (3.56%), Nantahala Capital Management LLC (3.12%), Laurion Capital Management LP (1.86%), Affinity Asset Advisors LLC (1.62%), Sio Capital Management LLC (0.66%) and Renaissance Technologies LLC (0.61%). Insiders that own company stock include Dennis D Kim and Sujal Shah.
View institutional ownership trends
.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $4.05.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $342.95 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.